Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction.
Our aim was to study the aging effects on the in vitro biological properties of bone marrow-derived mesenchymal stem cells (BMSCs) for construction of tissue-engineered heart valves. BMSCs were taken from teenagers with congenital heart diseases, and middle-aged and elderly patients with valvular diseases. Proliferative abilities were compared among the three groups by using colony-forming unit counting and growth curves (5-bromo-2'-deoxyuridine assay). Cell differentiation, vascular endothelial growth factor (VEGF) release under hypoxic condition, and migratory abilities were compared as well. Colony-forming units in the teenage group were significantly greater than those in the other two groups (P < 0.05), and significantly higher counts were observed in the middle age group than in the aged group (P < 0.05). Growth curves presented similar trends in which cells' proliferative abilities in the aged group decreased significantly (P < 0.05), while no differences were noted between the two nonaged groups. The differentiation potential to endothelial cells, osteoblasts and adipocytes, VEGF releases, and migratory abilities differed significantly between the aged group and nonaged groups (P < 0.05). However, no differences were noted between the two nonaged groups. BMSCs from older patients with heart valve diseases could be harvested and expanded successfully, and the phenotype and morphology were uniform as nonaged groups. However, the proliferative and differentiation properties of aged cells, as well as cytokine release and migratory abilities, are significantly impaired.
Xin
Yuan
Y
Department of Surgery, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wang
Yu-mei
YM
Zhang
Hao
H
Li
Jun
J
Wang
Wei
W
Wei
Ying-jie
YJ
Hu
Sheng-shou
SS
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D001854:Bone Marrow Cells / Q000378:metabolism / Q000502:physiology*; D002454:Cell Differentiation; D015687:Cell Hypoxia; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D016922:Cellular Senescence; D002648:Child; D016207:Cytokines / Q000378:metabolism; D006330:Heart Defects, Congenital / Q000473:pathology; D006349:Heart Valve Diseases / Q000473:pathology; D006351:Heart Valves / Q000166:cytology*; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000378:metabolism / Q000502:physiology*; D010641:Phenotype; D013997:Time Factors; D023822:Tissue Engineering; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D055815:Young Adult
D016207:Cytokines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A